
    
      The study will have an Experimental Arm and a Control Arm.

      Experimental Arm:

      Patients may receive repeated ASP-1929 PIT interventions for a period of up to 12 months
      after randomization until the patient has complete remission, progressive disease that is no
      longer amendable to study treatment, patient experiences intolerable side effects, or patient
      discontinues study treatment.

      Control Arm:

      Patients may be treated with physician's choice SOC until the patient has progressive
      disease, patient experiences intolerable side effects, or patient discontinues study
      treatment.
    
  